



Peroxisome proliferator-activated receptor gamma (PPARG) modulates free fatty acid receptor 1 (FFAR1) dependent insulin secretion in humans

Robert Wagner^{1,2,3}, Anja Hieronimus^{1,2,3}, Apostolia Lamprinou^{1,2,3}, Martin Heni^{1,2,3}, Erifili Hatzigelaki⁴, Susanne Ullrich^{1,2,3}, Norbert Stefan^{1,2,3}, Harald Staiger^{1,2,3}, Hans-Ulrich Häring^{1,2,3}, Andreas Fritsche^{1,2,3,*}

ABSTRACT

Genetic variation in *FFAR1* modulates insulin secretion dependent on non-esterified fatty acid (NEFA) concentrations. We previously demonstrated lower insulin secretion in minor allele carriers of *PPARG* Pro12Ala in high-NEFA environment, but the mode of action could not be revealed. We tested if this effect is mediated by *FFAR1* in humans. Subjects with increased risk of diabetes who underwent oral glucose tolerance tests were genotyped for 7 tagging SNPs in *FFAR1* and *PPARG* Pro12Ala. The *FFAR1* SNPs rs12462800 and rs10422744 demonstrated interactions with *PPARG* on insulin secretion. *FFAR1* rs12462800 ($p = 0.0006$) and rs10422744 ($p = 0.001$) were associated with reduced insulin secretion in participants concomitantly carrying the *PPARG* minor allele and having high fasting FFA. These results suggest that the minor allele of the *PPARG* SNP exposes its carriers to modulatory effects of *FFAR1* on insulin secretion. This subphenotype may define altered responsiveness to *FFAR1*-agonists, and should be investigated in further studies.

© 2014 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

Keywords *FFAR1*; Free fatty acid receptor 1; G-protein coupled receptor 40; GPR40; *PPARG*; Insulin secretion

1. INTRODUCTION

In addition to glucose, which is the foremost stimulator of insulin secretion in beta-cells, other nutrients such as free fatty acids (also called non-esterified fatty acids, NEFA) contribute to glucose-stimulated insulin secretion (GSIS). Glucose triggers the processes leading to insulin secretion by its metabolism within beta-cells [1,2]. NEFA also act as fuels in beta-cells and they are able to modulate insulin secretion by influencing intracellular metabolism [3]. It was not until 2003, the discovery of the role of a previously orphaned receptor, the G-protein-coupled receptor 40 (GPR40), now called free fatty acid receptor 1 (FFAR1), that an additional important coupling mechanism between NEFA and insulin secretion was revealed [4]. The acute increase of insulin secretion after raising NEFA levels was shown to be ~50% in healthy volunteers [5,6], and the *FFAR1*-pathway is thought to be involved in at least 50% of NEFA-mediated insulin secretion [7]. *FFAR1*-agonists have been developed to enhance GSIS, some of which could be candidates for a new class of antidiabetic drugs [8]. We recently demonstrated that *FFAR1*-agonism may be protective against

beta-cell apoptosis and provided evidence that common variation near the *FFAR1* gene modulates insulin secretion dependent on free-fatty acid levels [9].

Recent data from an investigation conducted with beta-cell cultures and animals suggest that *FFAR1* gene expression is modulated by stimulation of peroxisome proliferator-activated receptor gamma (*PPARG*) [10]. Intriguingly, in 2001 we had demonstrated effects of the *PPARG* Pro12Ala single nucleotide polymorphism (SNP) on insulin secretion in an elevated NEFA milieu. In this investigation, carriers of the minor allele of the Pro12Ala polymorphism (rs1805192) had lower insulin secretion during hyperglycemic clamp studies conducted with a concomitant intravenous lipid infusion, but no difference was seen between the genotypes without increasing NEFA [11].

Given these data supporting a crosstalk between *PPARG* and *FFAR1* signaling, we set out to look for evidence of a *PPARG* × *FFAR1* interaction in humans. For this purpose, we analyzed insulin secretion effects of interactions between previously described tagging SNPs in *FFAR1* [9] and the aforementioned diabetes-related SNP in *PPARG*, also accounting for NEFA levels.

¹Department of Internal Medicine, Division of Endocrinology, Diabetology, Nephrology, Vascular Disease and Clinical Chemistry, University Hospital of the Eberhard Karls University, Tübingen, Germany ²Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Centre Munich at the University of Tübingen (IDM), Tübingen, Germany ³German Center for Diabetes Research (DZD), Neuherberg, Germany ⁴2nd Department of Internal Medicine, Research Institute and Diabetes Center, Athens University Medical School, "Attikon" University Hospital, Athens, Greece

*Corresponding author. Otfried-Müller-Str 10, 72076 Tübingen, Germany. Tel.: +49 70712980590. E-mail: andreas.fritsche@med.uni-tuebingen.de (A. Fritsche).

Abbreviations: *FFAR1*, free fatty acid receptor 1; GPR40, G-protein coupled receptor 40; NEFA, non-esterified fatty acids; OGTT, oral glucose tolerance test; TUEF, Tübingen Family Study

Received June 3, 2014 • Revision received June 25, 2014 • Accepted July 1, 2014 • Available online 7 July 2014

<http://dx.doi.org/10.1016/j.molmet.2014.07.001>

2. METHODS

2.1. Study population

Subjects analyzed in the current study are participants of the Tuebingen Family Study (TUEF). TUEF is a cross-sectional observational study originally designed to characterize the phenotype of increased risk for type 2 diabetes. Persons with either a positive family history, or prior gestational diabetes or known glucose intolerance or overweight from Southern Germany were enrolled. For this analysis, we selected 1928 participants without incident diabetes who had fasting NEFA and full 5-point OGTT measurements for glucose and insulin, and who were also genotyped for the *PPARG* and *FFAR1* SNPs. Of the study population, 3% had prior gestational diabetes, 43% had a family history of diabetes in at least one first degree relative and 40% were obese according to the WHO definition ($\text{BMI} > 30 \text{ kg/m}^2$) (Table 1).

2.2. OGTT and laboratory measurements

Following an overnight fast, all participants ingested a 75 g glucose dose at 8 am (OGTT). Plasma glucose, insulin, C-peptide and NEFA concentrations were determined after 0, 30, 60, 90 and 120 min. A bedside glucose analyzer (glucose-oxidase method, Yellow Springs Instruments, Yellow Springs, OH, USA) was used to determine plasma glucose. Plasma insulin and NEFA were measured with commercial chemiluminescence assays for ADVIA Centaur (Siemens Healthcare Diagnostics, Eschborn, Germany).

2.3. Selection of tagging SNPs and genotyping

Selection of the tagging SNPs in *FFAR1* was performed as described earlier [9]. Genotyping was carried out on the MassARRAY platform from Sequenom (Sequenom, San Diego, CA, USA). Initially 9 SNPs were selected as tagging SNPs in *FFAR1* covering all other common SNPs within the locus with an $r^2 > 0.8$ (100% coverage), but genotype calling was unsuccessful for rs12459138 and Hardy–Weinberg equilibrium was rejected for rs10423648 ($p < 0.05$), therefore 7 SNPs went into analysis.

2.4. Calculations and statistics

Insulin sensitivity was assessed from 5-point OGTT glucose and insulin values using the Matsuda index (ISI), calculated as

$$\frac{10,000}{\sqrt{g_0 \times i_0 \times \frac{g_0 + g_{30} + g_{60} + g_{90} + g_{120}}{5} \times \frac{i_0 + i_{30} + i_{60} + i_{90} + i_{120}}{5}}}$$

Table 1 — Demographic and metabolic characteristics of the investigated population ($N = 1928$).

Trait	Median	IQR
Age	39	(29, 50)
BMI (kg/m^2)	28	(24, 35)
Glucose 0' (fasting, mmol/l)	5.1	(4.8, 5.4)
Glucose 120' (post-challenge, mmol/l)	6.2	(5.2, 7.3)
HbA1c (%)	5.4	(5.1, 5.7)
Insulin 0' (fasting, pmol/l)	51.0	(34.0, 87.0)
Insulin sensitivity index (AU)	12.4	(7.3, 20.5)
Insulinogenic index (AU)	124	(76, 200)
Non-esterified fatty acids (fasting, $\mu\text{mol/l}$)	561	(424, 723)
Triglycerides (fasting, mg/dl)	100	(71, 147)
Cholesterol (fasting, mg/dl)	190	(167, 215)
LDL (fasting, mg/dl)	116	(96, 139)
HDL (fasting, mg/dl)	52	(44, 62)

where g and i denote glucose and insulin levels, respectively, at the given time-point (minutes) of OGTT [12]. Insulin secretion was assessed by the insulinogenic index (IGI) which was originally proposed by Seltzer et al. in 1967 [13], and has been since then validated several times as a reliable measure of insulin secretion utilizing insulin and glucose measurements during the first 30 min of an OGTT [14,15]. IGI can be calculated as $(i_{30} - i_0)/(g_{30} - g_0)$. The disposition index (DI), another measure of insulin secretion which also accounts for insulin sensitivity, was calculated as $\text{IGI} \times \text{ISI}$.

Variables with skewed distributions were $\log_e$ -transformed prior to linear regression analyses. To increase statistical power in the interaction analyses, genotypes were coded according to the dominant inheritance model. Given the 7 investigated SNPs, to reduce the risk of false positive findings with multiple testing, the limit of statistical significance was defined at $0.05/7 = 0.007$, and a p between 0.05 and 0.007 was termed nominally significant. Sex, age and insulin sensitivity were used as covariates of IGI. Sex and age were used as covariates of DI. Interaction of the *FFAR1* SNPs with the *PPARG* SNP and with NEFA was tested adding all combinations of possible interaction terms (*FFAR1* $\times$ NEFA, *PPARG* $\times$ NEFA, *FFAR1* $\times$ *PPARG*, *FFAR1* $\times$ *PPARG* $\times$ NEFA) to the models. Effect estimates are given as standardized beta (β). All statistical analyses were conducted with JMP11 (SAS).

3. RESULTS

As expected, *PPARG* genotypes alone did not impact insulin secretion in the study population (a table on the genotype-dependent distribution of key cohort phenotypes is provided as [Supplementary Table 1](#)). To test the hypothesis that there is an interaction between genetic variation in *PPARG* and *FFAR1* on insulin secretion, we analyzed gene $\times$ gene interactions between rs1805192 in *PPARG* and 7 tagging SNPs of known frequent variants in *FFAR1*. Since the modulatory effect of *PPARG* on insulin secretion manifested only in a high-NEFA environment [11] and *FFAR1* effects on insulin secretion were seen only in interaction with fasting NEFA [9], we additionally adjusted for fasting NEFA and added interaction terms of fasting NEFA with the *FFAR1* SNPs and the *PPARG* SNP to the models.

We adjusted insulin secretion as determined by the insulinogenic index for sex, age, insulin sensitivity, fasting NEFA, *PPARG* Pro12Ala genotype, *FFAR1* genotypes and 4 interaction terms: between *FFAR1* and *PPARG* genotypes, between *PPARG* genotype and NEFA level, between *FFAR1* genotype and NEFA and, finally, a 3-way interaction term with *PPARG* $\times$ NEFA $\times$ *FFAR1*-SNP. We found a significant gene $\times$ gene interaction between the *FFAR1* SNP rs10422744 and the *PPARG* Pro12Ala SNP ($p = 0.005$) with a concomitant nominally significant interaction between NEFA level and the *PPARG* SNP ($p = 0.03$). Additionally, a nominally significant interaction was found between rs12462800 and *PPARG* ($p = 0.01$) with a concomitant *PPARG* $\times$ NEFA interaction ($p = 0.03$). The 3-way interaction term did not reach statistical significance, although the p -value of 0.0592 suggested a trend for nominal significance in the case of rs12462800. Detailed results of the interaction tests are provided in [Supplementary Table 2](#). An additional adjustment for obesity by adding BMI to the interaction models did not relevantly change the results (data not shown). Alternatively using DI as outcome variable, the gene $\times$ gene interaction term had a p -value of 0.01 and 0.001 for rs12462800 and rs10422744, respectively.

Next, we conducted subgroup analyses with stratification along interaction variables, namely the *PPARG* SNP and fasting NEFA. The study population was thus stratified into high and low NEFA (along the median NEFA, 561 $\mu\text{mol/L}$), and *PPARG* minor allele (Ala) carriers. This




Figure 1: Insulin secretion per **rs12462800** (A) and **rs10422744** (B) genotype in *FFAR1* in interaction with the *PPARG* Pro12Ala genotype and fasting free fatty acid levels. The bar charts show insulin secretion as residuals of the insulinogenic index adjusted for sex, age and insulin sensitivity (arbitrary units). Dark shaded bar charts represent homozygous carriers of the major *FFAR1* alleles (G/G for rs12462800 and C/C for rs10422744), while light shaded bar charts represent hetero- and homozygous carriers of the minor alleles (X/A for rs12462800 and X/T for rs10422744). The sets of bar charts in the left sided quadrants (I, III) show insulin secretion in the subgroup with the homozygous major *PPARG* allele (Pro/Pro), while the sets of bar charts in the right sided quadrants (II, IV) show insulin secretion in the subgroup that hetero- or homozygously carries the minor *PPARG* allele (X/Ala). The upper (I, II) and lower (III, IV) bar chart sets represent the subgroups with low and high fasting non-esterified fatty acid (NEFA) levels, respectively. This stratification was performed along the median NEFA value (561 $\mu\text{mol/l}$) of the total study population.

stratification resulted in 4 subgroups (I: low NEFA and PPARG Pro homozygotes, $n = 718$, II: low NEFA and PPARG Ala carriers, $n = 237$, III: high NEFA and PPARG Pro homozygotes, $n = 744$, IV: high NEFA and PPARG Ala carriers, $n = 229$). An effect of the *FFAR1* genotype on insulin secretion was only evident in the subgroup IV comprising participants with at least one PPARG Ala allele and high fasting NEFA (Figure 1A and B bottom right diagrams [diagrams IV]). In this subpopulation, carriers of the minor allele of rs10422744 and rs12462800 in *FFAR1* had lower insulin secretion ($\beta = -0.18$, $p = 0.001$ and $\beta = -0.19$, $p = 0.0006$, respectively) than homozygotes of the major allele, after controlling for sex, age and insulin sensitivity.

4. DISCUSSION

In this work, we provide evidence for a biologically relevant crosstalk between PPARG and FFAR1 signaling in the regulation of insulin secretion in humans. Importantly, this crosstalk was only manifest when fasting NEFA levels were high.

The Pro12Ala variant in *PPARG* has been one of the first candidate SNPs for type 2 diabetes [16,17]. The rare allele of this variant is associated with a 25% reduced risk for the disease [18]. Given the role of PPARG as both a receptor for NEFA and itself a regulator of fat metabolism, our group had earlier investigated the hypothesis that PPARG-mediated alterations in fatty acid signaling could have an impact on insulin secretion. In those hyperglycemic clamp studies, we had compared insulin secretion between Pro/Pro and X/Ala carriers of the PPARG variant in a control and a high-NEFA setting. Only the clamp condition with a concomitant infusion of Intralipid solution, performed to raise NEFA levels, had unmasked striking differences in insulin secretion between *PPARG* genotypes [11]. However, no explanation could be given for the mechanism of action by that time. Meanwhile, the NEFA receptor FFAR1 has been established as an important stimulator of fatty-acid mediated insulin secretion [4] and genetic variation in *FFAR1* has been shown to influence beta-cell function [9,19]. Therefore, FFAR1 seemed to be a plausible link between PPARG and insulin secretion. By analyzing the previously described 7 *FFAR1* tagging SNPs, we now found 2 SNPs, which exert a NEFA and PPARG-dependent effect on insulin secretion.

The SNPs rs12462800 and rs10422744 are located 0.8 kb apart in an intergenic regulatory area between the *FFAR1* (*GPR40*) and *FFAR3* (*GPR41*) genes, 3.5 and 3.8 kb from the 3' end of the single *FFAR1* exon. These SNPs are more distal from the gene than the previously described *FFAR1* SNP rs1573611 which directly interacts with fasting NEFA in association with insulin secretion [9].

The molecular mechanisms underlying the PPARG–FFAR1 interaction are still speculative. Although the literature is controversial, there is a wealth of data from basic science and clinical studies involving the use of PPARG agonists (thiazolidinediones) indicating that PPARG activation may have a positive impact on beta-cell function and beta-cell survival (reviewed by [20]). The PPARG–FFAR1 interaction, especially in light of the effect modification by NEFA levels, could possibly explain this still poorly understood link between PPARG action and beta-cell function. A recent study demonstrated that PPARG overexpression leads to an increased expression of FFAR1 in rat INS-1 cells and primary rat islets [10]. A possible interaction scenario could thus be a defective PPARG-induced transcriptional or translational activity of the FFAR1 gene in the presence of the *FFAR1* minor allele variants, which would consecutively result in a limited compensatory potential to increase insulin secretion when fasting NEFA are elevated. The fundamental human phenotypic alterations associated with the Pro12Ala variant seem to involve lipolysis and its insulin-dependent inhibition

[21–23]. Since FFAR1 is activated by medium and long-chained fatty acids [24], perturbations in NEFA levels or their composition as a consequence of altered PPARG action could modulate insulin secretion through FFAR1.

In summary, PPARG and FFAR1 are connected in several ways, and the presented interaction is mechanistically reasonable. Additional investigations are required to elucidate the exact details of the underlying physiology. However, our findings are of immanent importance for the treatment of type 2 diabetes, because the described genotypic interaction between PPARG and FFAR1 could have bearing on the pharmacologic efficacy of FFAR1 agonists. Although a phase 3 clinical trial of the most promising FFAR1-agonist has been recently halted, several of such agents are still under development [8,25]. We infer that the variants identified in the current study, under the constellation of the minor PPARG Pro12Ala allele, could have relevant impact on the effectiveness of FFAR1 agonists. Identification of variants which are candidates for pharmacogenetic interactions could pave the way for investigating genotype-based therapeutic responses within clinical studies and on the long run in clinical practice. This would eventually lead to an improved selection of individuals who would benefit from specific therapies [26].

ACKNOWLEDGMENTS

We thank all the research volunteers for their participation. We gratefully acknowledge the excellent technical assistance of Anna Bury, Anja Dessecker, Dr. Louise Fritsche, Ellen Kollmar, Corinna Sailer and Andreas Vosseler (all University of Tübingen, Germany).

CONFLICT OF INTEREST

None declared.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.molmet.2014.07.001>.

REFERENCES

- [1] Brisson, G.R., Malaisse-Lagae, F., Malaisse, W.J., 1972. The stimulus-secretion coupling of glucose-induced insulin release. VII. A proposed site of action for adenosine-3',5'-cyclic monophosphate. *The Journal of Clinical Investigation* 51:232–241. <http://dx.doi.org/10.1172/JCI106808>.
- [2] Meglasson, M.D., Matschinsky, F.M., 1986. Pancreatic islet glucose metabolism and regulation of insulin secretion. *Diabetes/Metabolism Reviews* 2: 163–214. <http://dx.doi.org/10.1002/dmr.5610020301>.
- [3] Nolan, C.J., Madiraju, M.S.R., Delghingaro-Augusto, V., Peyot, M.-L., Prentki, M., 2006. Fatty acid signaling in the beta-cell and insulin secretion. *Diabetes* 55(Suppl. 2):S16–S23. <http://dx.doi.org/10.2337/diabetes>.
- [4] Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., et al., 2003. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. *Nature* 422:173–176. <http://dx.doi.org/10.1038/nature01478>.
- [5] Boden, G., Chen, X., Rosner, J., Barton, M., 1995. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. *Diabetes* 44:1239–1242. <http://dx.doi.org/10.2337/diab.44.10.1239>.
- [6] Kashyap, S., Belfort, R., Gastaldelli, A., Pratipanawatr, T., Berria, R., Pratipanawatr, W., et al., 2003. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to

- develop type 2 diabetes. *Diabetes* 52:2461–2474. <http://dx.doi.org/10.2337/diabetes.52.10.2461>.
- [7] Prentki, M., Matschinsky, F.M., Madiraju, S.R.M., 2013. Metabolic signaling in fuel-induced insulin secretion. *Cell Metabolism* 18:162–185. <http://dx.doi.org/10.1016/j.cmet.2013.05.018>.
- [8] Poitout, V., Lin, D.C.-H., 2013. Modulating GPR40: therapeutic promise and potential in diabetes. *Drug Discovery Today* 18:1301–1308. <http://dx.doi.org/10.1016/j.drudis.2013.09.003>.
- [9] Wagner, R., Kaiser, G., Gerst, F., Christiansen, E., Due-Hansen, M.E., Grundmann, M., et al., 2013. Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of insulin secretion in humans. *Diabetes* 62:2106–2111. <http://dx.doi.org/10.2337/db12-1249>.
- [10] Kim, H.-S., Hwang, Y.-C., Koo, S.-H., Park, K.S., Lee, M.-S., Kim, K.-W., et al., 2013. PPAR- γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β -cells. *PLoS ONE* 8: e50128. <http://dx.doi.org/10.1371/journal.pone.0050128>.
- [11] Stefan, N., Fritsche, A., Häring, H., Stumvoll, M., 2001. Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor- γ 2 gene. *Diabetes* 50:1143–1148. <http://dx.doi.org/10.2337/diabetes.50.5.1143>.
- [12] Matsuda, M., DeFronzo, R.A., 1999. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. *Diabetes Care* 22:1462–1470.
- [13] Seltzer, H.S., Allen, E.W., Herron Jr., A.L., Brennan, M.T., 1967. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. *The Journal of Clinical Investigation* 46:323–335. <http://dx.doi.org/10.1172/JCI105534>.
- [14] Albareda, M., Rodríguez-Espinosa, J., Murugo, M., de Leiva, A., Corcoy, R., 2000. Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. *Diabetologia* 43:1507–1511. <http://dx.doi.org/10.1007/s001250051561>.
- [15] Hanson, R.L., Pratley, R.E., Bogardus, C., Narayan, K.M.V., Roumain, J.M.L., Imperatore, G., et al., 2000. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. *The American Journal of Epidemiology* 151:190–198.
- [16] Deeb, S.S., Fajas, L., Nemoto, M., Pihlajamäki, J., Mykkänen, L., Kuusisto, et al., 1998. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. *Nature Genetics* 20:284–287. <http://dx.doi.org/10.1038/3099>.
- [17] Altshuler, D., Hirschhorn, J.N., Klannemark, M., Lindgren, C.M., Vohl, M.C., Nemesh, J., et al., 2000. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. *Nature Genetics* 26:76–80. <http://dx.doi.org/10.1038/79216>.
- [18] Stumvoll, M., Häring, H., 2002. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. *Diabetes* 51:2341–2347.
- [19] Kalis, M., Levéen, P., Lyssenko, V., Almgren, P., Groop, L., Cilio, C.M., 2007. Variants in the FFAR1 gene are associated with beta cell function. *PLoS ONE* 2: e1090. <http://dx.doi.org/10.1371/journal.pone.0001090>.
- [20] Gupta, D., Kono, T., Evans-Molina, C., 2010. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. *Diabetes, Obesity and Metabolism* 12:1036–1047. <http://dx.doi.org/10.1111/j.1463-1326.2010.01299.x>.
- [21] Stumvoll, M., Wahl, H.G., Lohlein, K., Becker, R., Machicao, F., Jacob, S., et al., 2001. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-2 gene is associated with increased antilipolytic insulin sensitivity. *Diabetes* 50:876–881. <http://dx.doi.org/10.2337/diabetes.50.4.876>.
- [22] Stumvoll, M., Häring, H., 2002. Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPARgamma2? *Diabetologia* 45:152–153. <http://dx.doi.org/10.1007/s001250200018>.
- [23] Vangipurapu, J., Stančáková, A., Pihlajamäki, J., Kuulasmaa, T.M., Kuulasmaa, T., Paananen, J., et al., 2011. Association of indices of liver and adipocyte insulin resistance with 19 confirmed susceptibility loci for type 2 diabetes in 6,733 non-diabetic Finnish men. *Diabetologia* 54:563–571. <http://dx.doi.org/10.1007/s00125-010-1977-4>.
- [24] Ichimura, A., Hirasawa, A., Hara, T., Tsujimoto, G., 2009. Free fatty acid receptors act as nutrient sensors to regulate energy homeostasis. *Prostaglandins & Other Lipid Mediators* 89:82–88. <http://dx.doi.org/10.1016/j.prostaglandins.2009.05.003>.
- [25] Lead GPR40 agonist bites the dust. *Nature Review Drug Discovery* 13, 2014: 91. <http://dx.doi.org/10.1038/nrd4246>.
- [26] Wagner, R., Staiger, H., Ullrich, S., Stefan, N., Fritsche, A., Häring, H.-U., 2014. Untangling the interplay of genetic and metabolic influences on beta-cell function: examples of potential therapeutic implications involving TCF7L2 and FFAR1. *Molecular Metabolism* 3:261–267. <http://dx.doi.org/10.1016/j.molmet.2014.01.001>.